-+ 0.00%
-+ 0.00%
-+ 0.00%

Beam Therapeutics' risto-cel meets primary endpoints in sickle cell trial

PUBT·11/10/2026 12:07:11
Listen to the news
Beam Therapeutics' risto-cel meets primary endpoints in sickle cell trial
  • Beam Therapeutics reported positive pivotal results from its BEACON Phase 1/2 trial of risto-cel, an investigational one-time treatment for sickle cell disease.
  • The trial met its main efficacy goal of sustained freedom from severe vaso-occlusive crises, with all primary safety and secondary endpoints met.
  • The results support a planned U.S. biologics license application submission as early as year-end 2026.
  • Detailed pivotal results will be presented at a medical meeting in 2027.
  • Earlier trial results will be presented at the American Society of Hematology annual meeting in New Orleans on December 12-15, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9873987) on November 10, 2026, and is solely responsible for the information contained therein.